Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1681
    +0.0025 (+0.21%)
     
  • GBP/USD

    1.2497
    -0.0014 (-0.11%)
     
  • Bitcoin GBP

    51,249.63
    -525.00 (-1.01%)
     
  • CMC Crypto 200

    1,331.91
    -64.62 (-4.63%)
     
  • S&P 500

    5,107.88
    +59.46 (+1.18%)
     
  • DOW

    38,316.59
    +230.79 (+0.61%)
     
  • CRUDE OIL

    83.95
    +0.38 (+0.45%)
     
  • GOLD FUTURES

    2,350.00
    +7.50 (+0.32%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Merck’s Immunology and Cardiovascular Franchise in 3Q17

In 3Q17, Merck's Remicade revenues fell ~31% to $214 million compared to $311 million in 3Q16. The fall was driven by lower sales due to generic competition and biosimilars.